

| | |
|---|--|
| CEO | Severin Schwan |
| Chairman of the Board | Franz B. Humer |
| Headquarters | Basel, Switzerland |
| Company Structure | |
| Pharmaceuticals | Roche Pharmaceuticals Genentech Chugai |
| Diagnostics | Roche Applied Sciences Roche Molecular Diagnostics Roche Professional Diagnostics Roche Tissue Diagnostics Roche Diabetes Care |
| Major R&D sites | Focus |
| Basel | Metabolism, Central Nervous System |
| Nutley | Oncology |
| Palo Alto | Inflammation, Virology |
| Penzberg | Diagnostics |
| Kulmbach | RNAi |
| Mannheim | Diagnostics |
| Rotkreuz | Diagnostics |
| Pleasanton | Diagnostics |
| Ventana Medical Systems (Tucson, Arizona) | Tissue Diagnostics |
| Shanghai | China R&D Center |
| Chugai (Tokyo) | |
| Genentech (South San Francisco) | |
| Major production sites | Roche's global Pharma Manufacturing network consists of 20 sites. It comprises 5 chemical, 2 Biotech and 13 galenic units |
| Web site address | www.roche.com |
| Stock exchange listings | SWX Swiss Exchange |

| | |
|---------------------------------|---|
| 2008 Sales | 45,617 billion Swiss francs |
| Pharmaceuticals | 36.0 billion Swiss francs |
| Diagnostics | 9.7 billion Swiss francs |
| 2008 R&D at a glance | Group expenditure: nearly 9 billion Swiss francs |
| Pharmaceuticals | R&D pipeline: 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications 13 major approvals gained Filing of 11 major new marketing applications 22 % of sales dedicated to R&D |
| Diagnostics | 3 FDA approvals in Molecular Diagnostics 5 new immunoassays Nearly 10% of sales dedicated to R&D |
| 2008 employees | Over 80.000 worldwide |